New Hampshire House Bill HB1292

New Hampshire 2026 Regular Session

• Introduced: 12/1/25
• Refer: 12/1/25

Caption

Expanding the right to try act to include certain qualifying severe illness and permitting certain regenerative stem cell therapies under the act.

Impact

The legislation aims to enhance patients' rights by enabling them to access potentially life-saving therapies that are not yet approved by the FDA. It allows patients diagnosed with severe illnesses to seek treatments that may significantly improve their quality of life, especially in situations where conventional treatment options have failed. By fostering a more encouraging environment for the use of innovative medical therapies, the bill is expected to promote the development of advanced medical solutions within the state.

Summary

House Bill 1292 seeks to expand the existing Right to Try Act in New Hampshire to include patients suffering from qualifying severe illnesses. This amendment allows access to unapproved drugs, biologics, and devices under specific conditions, aimed at providing treatment options for those with chronic and debilitating health issues. Moreover, the bill introduces regulations concerning regenerative stem cell therapies, ensuring that such treatments adhere to ethical standards and quality controls.

Sentiment

The sentiment surrounding HB 1292 reflects a mix of hopefulness and caution. Proponents argue that the bill addresses a critical gap in treatment options for patients with severe illnesses, emphasizing the importance of personal choice in health care. However, there are concerns from some quarters regarding the ethical implications of expanding access to unapproved therapies, particularly around the safety and regulatory measures in place. This debate highlights the tension between the urgency of treating terminal conditions and the importance of safeguarding public health.

Contention

Notable points of contention involve the ethical sourcing of stem cells used in treatments and the adequacy of the safeguards established within the bill. Critics point out potential risks associated with untested therapies, emphasizing the need for rigorous standards to prevent exploitation of vulnerable patients. Additionally, there are apprehensions about how effectively the bill can balance innovation in treatment with the necessary regulatory oversight to ensure patient safety.